Tampa St. Petersburg, FL, July 21, 2026 — Novo Nordisk, the pharmaceutical company known for its popular weight-loss medications Ozempic and Wegovy, has initiated legal action against competitor Eli Lilly. The lawsuit, filed in the Tampa-St. Petersburg (Sarasota) area, centers on allegations that Eli Lilly has engaged in deceptive advertising practices concerning its own weight-loss drug, Zepbound.

Novo Nordisk contends that Eli Lilly’s promotional materials for Zepbound falsely imply the drug’s superiority over Wegovy. According to Novo Nordisk, these claims are based on the comparison of outdated clinical trial data. The company asserts that this practice misleads consumers and unfairly positions Zepbound in the market.

In its lawsuit, Novo Nordisk is seeking specific remedies. The company is requesting that Eli Lilly cease airing or distributing the challenged advertisements. Additionally, Novo Nordisk is seeking financial damages as a result of the alleged deceptive advertising.

The core of Novo Nordisk’s complaint revolves around the comparative efficacy claims made in Eli Lilly’s advertising. By allegedly using historical or incomplete data, Novo Nordisk argues that Eli Lilly is creating a misleading impression of Zepbound’s performance relative to Wegovy. The legal filing aims to address what Novo Nordisk views as unfair competition stemming from these advertising tactics.


Story summarized from the original created by Scripps News Group on www.tampabay28.com, see more information here.

About The Author
SignalNews